Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double- Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of BL-8040 Addition to Consolidation Therapy in AML Patients

NCT02502968 is registered in ClinicalTrials.gov with Dr. Petra Tschanter as lead sponsor.

NCT NCT02502968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02502968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double- Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of BL-8040 Addition to Consolidation Therapy in AML Patients
Lead sponsor
Dr. Petra Tschanter
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2015
Completion date
Not reported
Enrollment
194 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia